Evaluation Value of Blood Biomarker Tests for Efficacy of EGFR-TKI in Advanced NSCLC Treatment

Objective To analyze the levels of serum CTCs and ctDNA in NSCLC patients receiving first-line EGFR-TKI treatment, and to explore the clinical value of CTCs and ctDNA detection in assessing the efficacy of treatment for advanced lung cancer. Methods A total of 109 NSCLC patients receiving first-line...

Full description

Saved in:
Bibliographic Details
Published inZhongliu fangzhi yanjiu Vol. 52; no. 5; pp. 382 - 387
Main Authors Fan, Rui, Wu, Yonghui, Gu, Zhan, Peng, Yanbin, Wang, Lixin
Format Journal Article
LanguageChinese
English
Published Tianjin China Anti-Cancer Association 2025
Magazine House of Cancer Research on Prevention and Treatment
Subjects
advanced nsclc
Biomarkers
circulating tumor cells
circulating tumor dna
Computed tomography
Effectiveness
efficacy
egfr-tki
Epidermal growth factor receptors
Lung cancer
Metastases
Non-small cell lung carcinoma
Patients
Risk groups
Subgroups
Survival
Tumor markers
Online AccessGet full text

Cover

More Information
Summary:Objective To analyze the levels of serum CTCs and ctDNA in NSCLC patients receiving first-line EGFR-TKI treatment, and to explore the clinical value of CTCs and ctDNA detection in assessing the efficacy of treatment for advanced lung cancer. Methods A total of 109 NSCLC patients receiving first-line EGFR-TKI treatment were enrolled. Serum tumor markers CEA, CTCs, and ctDNA were detected at baseline and after one month of treatment. Chest CT scans were performed, and treatment efficacy was evaluated based on RECIST1.1 criteria. CTCs were counted by enrichment-staining-computational algorithm to analyze malignant features, while ctDNA was assessed using digital PCR. Results Survival rate was low in patients with abnormal CEA and ctDNA tests at baseline and in patients with reduced serum CTCs after treatment. In the SD subgroup of patients with brain metastases and advanced stage, the PFS benefit was low. Conclusion Patients in the SD subgroup have significantly higher recurrence risks than those in the PR or CR subgroups. Therefore, CTC and ctDNA testing should be applied to patients in the SD subgroup to identify high-risk patients with poor response to EGFR-TKI treatment, intervene with additional treatment promptly, and obtain long progression-free survival.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1000-8578
DOI:10.3971/j.issn.1000-8578.2025.24.1017